Six NCI-designated cancer centers have agreed to pool data from their electronic medical record systems and cancer registries to accelerate discovery of targets and the development of biomarkers.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
